Filing Flows › PAVmed (PAVM) › Q2 2025
PAVmed (PAVM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
PAVmed (PAVM) reported revenue of $6K for the second quarter 2025 (Q2 2025), -99% from a year earlier and -25% from the quarter before.
PAVmed, Q2 2025: revenue $6K (-99% year over year), net loss $12.3M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6K | -25% | -99% |
| Operating profit | −$4.7M | — | — |
| Net earnings | −$12.3M | -166% | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $6K in Q2 2025, down 99% year over year and down 25% from the previous quarter.
Operating costs exceeded revenue by $4.7M, an operating margin of -78583.3%. Total costs fell 68% while revenue fell 99%. The quarter ended with a net loss of $12.3M, after a profit of $18.6M the previous quarter. Minority interests bore $403K of it: to shareholders the quarter was a loss of $11.9M. Net interest and other expense of $7.6M was the main reason.
Operating cash flow was −$1.2M. Non-cash charges added back $22K of depreciation and amortization and $162K of share-based compensation. Working capital and other items added $11.0M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$1.2M.
Questions
What was PAVmed's revenue in the second quarter 2025?
PAVmed (PAVM) reported revenue of $6K for the second quarter 2025 (Q2 2025), -99% from a year earlier and -25% from the quarter before.
Source: PAVmed 10-Q on SEC EDGAR.